STUDIES TO EVALUATE THE POTENTIAL FOR ENVIRONMENTAL&THERAPEUTIC AGENTS TO INDUCE IMMUNOTOXICITY - In vivo

NTP PAC混合物评估计划(PAC-MAP)提供了使用包括广泛终点的体外/短期体内测试电池评估单个多环芳烃(PAC)、已定义的PAC混合物和含有PAC的复杂环境样品的框架。部分PAC与广泛的毒性(致癌、免疫毒性、生殖和发育毒性、神经毒性)和一系列复杂的作用机制有关。特别是，许多PAC与体液免疫功能的抑制有关，免疫毒性已被确定为评估PAC致癌潜力的信息参数。作为预测混合效应的潜在测试电池的一部分，我们研究了13个单独的PAC和3个混合的PAC调节抗原特异性抗体反应和影响骨髓细胞学的可能性。21财年没有开始体内免疫毒理学研究，工作重点是数据分析和前几个合同年度进行的研究的报告/存档。BRT在21财年为单独的PAC-MAP免疫毒性研究提供了4份最终报告和3份草稿报告。BRT完成了另外5份报告，并为PAC MAP化学物质的免疫病理学研究提供了2份报告草稿。三(氯丙基)磷酸(TCPP)的发育免疫毒理学研究的最终报告也于21财年完成。此外，BRT结束了MPEP的免疫病理学研究，NTP审查了免疫毒性和抗病研究的报告草案。

The NTP PAC Mixtures Assessment Program (PAC-MAP) provides the framework for assessing a breadth of individual polycyclic aromatic compounds (PACs), defined PAC mixtures, and complex PAC-containing environmental samples using an in vitro/short-term in vivo testing battery that includes a broad spectrum of endpoints. Select PACs have been associated with a wide range of toxicities (carcinogenicity, immunotoxicity, reproductive and developmental toxicity, neurotoxicity) and a complicated array of mechanisms of action. In particular, many PACs have been associated with suppression of humoral immune function and immunotoxicity has been identified as an informative parameter for estimating the carcinogenic potential of PACs. As part of the potential testing battery to predict mixture effects, we have examined the potential for 13 individual PACs and 3 mixtures to modulate the antigen specific antibody response and affect bone marrow cytology. No in vivo immunotoxicology studies were started in FY21 and efforts were focused on data analysis and reporting/archiving of studies conducted in previous contract years. BRT provided 4 final reports and 3 draft reports for individual PAC-MAP immunotoxicity studies in FY21. BRT completed an additional 5 reports and provided 2 draft reports for immunopathology studies of the PAC MAP chemicals. The final report for the developmental immunotoxicology studies on Tris (Chloropropyl) phosphate (TCPP) was also completed in FY21. In addition, BRT closed the immunopathology study for MPEP, and draft reports for the immunotoxicity and disease resistances studies were reviewed by the NTP.